Physician profile
Michael A Avidano
NPI 1780680462
$2,948.68
in general payments reported to CMS, 2019-2025
13 companies · $211 in 2025
The $211 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $149 · 2021: $385 · 2022: $364 · 2023: $82.46 · 2024: $1,429 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,067 · Travel and Lodging: $656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,067.08 |
| Travel and Lodging | $655.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $1,398.56 | 2022-2025 | |
| Stryker Corporation | $593.08 | 2019-2022 | |
| Optinose US, INC. | $208.20 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $204.52 | 2022-2025 | Dupixent, Libtayo |
| Intersect Ent, INC. | $165.63 | 2019-2021 | |
| Genzyme Corporation | $156.43 | 2019-2025 | |
| Glaxosmithkline, LLC. | $73.71 | 2022-2025 | Nucala |
| Alk-Abello, INC | $56.92 | 2020-2022 | |
| Medtronic, INC. | $21.11 | 2021 | |
| Pentax of America, INC. | $20.60 | 2023 | N/A |
| Covidien LP | $18.20 | 2019 | |
| Merck Sharp & Dohme LLC | $17.08 | 2023 | |
| Hikma Pharmaceuticals USA | $14.64 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Avidano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.